Clinical Trial Detail

Clinical Trials

Clinical Trial Detail

WEE1 Inhibitor MK-1775 and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Complete title: ADVL1312, A PHASE 1/2 STUDY OF MK-1775 (AZD1775, IND# 121422) IN COMBINATION WITH ORAL IRINOTECAN IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY SOLID TUMORS

Research Study Number ADVL1312
 
Principal Investigator Julie Park, MD
 
Phase I/II

Research Study Description

This phase I/II trial studies the side effects and best dose of WEE1 inhibitor MK-1775 and irinotecan hydrochloride in treating younger patients with solid tumors that have come back or that have not responded to standard therapy. WEE1 inhibitor MK-1775 and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number ADVL1312
 
Contact Advanced Therapeutics Study Line
 
Telephone 206/987-2553
 
E-mail
 

Keywords: Glioma; Pediatric Cancers, Miscellaneous; Neuroblastoma; Solid Tumors; Neoplasms, Germ Cell and Embryonal; Neuroectodermal Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials